Castor EDC and OpenClinica are both positioned as clinical trial data capture systems, but the public documentation emphasizes different operating priorities. Castor's materials describe an API-driven platform with broader connected trial components, AI-assisted source-to-EDC extraction, and promotional build-time claims for lower-complexity studies [1][7][8]. OpenClinica's materials emphasize a modular EDC with free expert-managed study build, CDISC ODM XML import and retrieval, and an explicit focus on small to mid-size sponsors, CROs, and academic teams [10][9][11]. A direct decision requires separating documented workflow scope from unsupported vendor metrics and recognizing that the two sources describe overlapping but not identical operating models. This comparison identifies what each product's public documentation substantiates, where the claims diverge, and which buyer questions remain unanswerable from the public materials.

Study Build and Deployment Claims Are Stated in Different Terms

Castor's EDC pages state that the platform ranks among the top 5% of EDC software providers for shortest platform build time, that low-complexity studies can deploy in as little as 3-4 weeks, and that build times can be reduced by up to 63% [1]. One page adds that more than 90% of Castor studies are deployed within the first four weeks [4]. These are vendor-reported figures tied to a specific product framing. The public pages do not publish the underlying sample, the denominator used for the top-5% ranking, or independent verification of the build-time reduction claim.

OpenClinica's materials state that builders can create studies in hours with drag-and-drop tools and templated CRFs, and that the company will perform a free expert-managed study build in days when a protocol is submitted [10]. Another page states launch in 2-3 weeks instead of 3-6 months [11]. The terms are not directly comparable to Castor's 3-4 week deployment and 63% reduction language because OpenClinica does not publish a comparable percentage claim or the study complexity categories used for its estimate. Both vendors describe speed, but using different units and without source-level denominators.

Data Capture and Integration Scope Differ in Public Detail

Castor's product pages describe integrating study data from EHR, eCRF, ePRO or eCOA, laboratory, wearables, and other devices into a single clinical trial data environment, with an open API and extensible integration framework [1]. The product materials also list remote enrollment, screening, eConsent, patient diaries, native apps, and video calls as components of an all-in-one platform [2][6]. These are documented as product capabilities, not as outcomes in a defined study population. The public pages support the scope of advertised components but do not establish performance for any particular protocol.

OpenClinica presents itself as modular, with EDC connectable to eConsent, eCOA, randomization, EHR-to-EDC, analytics, and patient recruitment tools when the buyer is ready [10]. Its documentation includes a Clinicaldata endpoint that imports or retrieves clinical data in JSON or CDISC ODM XML, including attachments through a ZIP file referenced by the XML [9][12]. OpenClinica's public material does not document the same AI extraction workflow that Castor describes. The different documentation depth means that integration capability is easiest to verify at the level of stated endpoints and product modules, not at the level of delivered interoperability outcomes.

A Suggested Buyer Audit Before Contacting Either Vendor

A practical approach is to assemble a short workflow test against each vendor's public documentation, not against third-party rankings. For Castor, request the OpenAPI specification, confirm which OAuth scope a planned integration would need, and ask for a written statement on whether any desired endpoint is in Beta, Stable, Deprecated, or Retired status under the published API lifecycle [3][5]. For OpenClinica, map a planned data import to the Clinicaldata API requirements, including authentication, role permissions, CDISC ODM OIDs, and whether the protocol needs file attachments via XML and ZIP [12].

Because the public Castor pages advertise AI clinical data extraction while the OpenClinica pages do not document a comparable source-to-EDC AI pipeline, a buyer testing claims should request evidence for any AI workflow promised during sales conversations. Similarly, because both companies state compliance with FDA 21 CFR Part 11, HIPAA, GDPR, and related standards, a buyer should ask for current certificates or attestations rather than treat a summary bullet as proof of certification [1][10]. If the decision turns on build speed, request the exact study complexity definition, the number of studies used, and whether the quoted time includes validation and deployment approvals [4][11].

API Documentation Reveals Distinct Integration Contracts

Castor publishes OpenAPI 2 specification documentation for a RESTful API, describing OAuth2 Client Credentials and supported Authorization Code flows, three OAuth2 scopes, and rate limiting set to 600 requests in 10 minutes unless an endpoint specifies otherwise [3]. A developer policy further describes deprecation procedures, Sunset HTTP response headers under RFC8594, and API access rules for load and user-agent identification [5]. These are operational constraints documented by Castor, not performance guarantees. A build team can evaluate the endpoint surface and versioning model directly from the published specification.

OpenClinica's reference guide details a Clinicaldata API for importing and retrieving participant clinical data in JSON or CDISC ODM XML, with role and study permission prerequisites and behavior that varies by user access level [12]. It also documents that file attachments are uploaded only through the XML Import API and warns that uploaded files are not validated against the item type [12]. This differs from Castor's API documentation focus, which centers on OAuth scopes, rate limits, and versioning. A buyer evaluating integration should compare the actual endpoint contracts, not assume that both platforms expose equivalent REST surfaces or equivalent file-handling rules.

Commercial Positioning and Service Obligations Point to Different Buyer Settings

Castor's materials describe an all-in-one clinical trial platform with eSource, DCT components, ePRO/eCOA, and an ecosystem of tools for sponsors and CROs [2][6]. The AI extraction documentation describes a service workflow in which a human reviewer confirms every extracted value before it is committed, with a 100% review policy today and risk-based review described as coming soon [7]. Those materials also report a manual time of 39 minutes per chart and an AI-assisted time of 6 minutes, plus manual cost of $48.75 and AI-assisted cost of $9.75, but label all non-cited figures as internal benchmarking, production telemetry, or anonymized case results, not peer-reviewed [7].

OpenClinica explicitly names small to mid-size sponsors, CROs, and academic teams as its audience and lists academic and investigator-initiated research, device and diagnostics studies, and remote or hybrid data capture among ideal use cases [10][11]. Its packages include CSM support and 24/5 application assistance according to the product page [10]. Castor's pages also describe best-in-class support and a customer-support resource link, but the two companies do not publish comparable service tiers or equivalent sample-based support metrics [1]. The public materials cannot settle whether one vendor provides stronger support for a particular study phase or regulatory context; they only show differently framed service promises.